Investigating the risk factors for antibiotic lock therapy failure in pediatric cancer: a single center retrospective analysis.

BACKGROUND Catheter-related bloodstream infection (CRBSI) is one of the most common complications of central lines. Data concerning the effectiveness and safety of antibiotic lock therapy (ALT), especially in pediatric hematology and oncology patients, have not yet reached sufficient levels of evidence. We aimed to share our center`s experience on ALT in pediatric cancer and to investigate the causes of ALT failure. METHODS All cases with CRBSI and treated with ALT administiration in children with cancer between January 2015 and May 2019 were reviewed. Patients characteristics, laboratory and clinical findings, treatments, outcome of ALT, recurrences and reinfections were recorded. Patients with successful and unsuccessful ALT outcomes were compared in order to identify the risk factors for ALT failure. RESULTS Sixteen eligible CRBSI treated with adjunctive ALT were identified. The most common pathogens were coagulase negative staphylococci (8/16, 50%). Treatment failure was observed in 31.2% (5/16). Younger age alone was an independent risk factor for treatment failure (0.9 vs 6.8 years, p = 0.038). Recurrence and reinfection rates were 23.1% and 16.7%. Mild bleeding occured in two cases (12.5%) and occlusion causing catheter removal was seen in one (6.3%). CONCLUSIONS ALT was found to be a safe modality with a success rate of 68.8% in children with cancer at our center and younger age was an independent risk factor for treatment failure. Future studies with larger sample sizes are needed to determine the factors affecting the ALT outcome, especially in childhood malignancies.

[1]  O. Muensterer,et al.  Central Venous Access Devices (CVAD) in Pediatric Oncology Patients—A Single-Center Retrospective Study Over More Than 9 Years , 2019, Front. Pediatr..

[2]  N. Maniadakis,et al.  Attributable length of stay and cost for pediatric and neonatal central line-associated bloodstream infections in Greece. , 2019, Journal of infection and public health.

[3]  Sara M. Federico,et al.  Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. , 2018, The Lancet. Infectious diseases.

[4]  E. Abdala,et al.  Role of Lock Therapy for Long-Term Catheter-Related Infections by Multidrug-Resistant Bacteria , 2018, Antimicrobial Agents and Chemotherapy.

[5]  P. Bookstaver,et al.  Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients. , 2017, International journal of antimicrobial agents.

[6]  Haluk Çokuğraş,et al.  Çocuk Hastalarda Kateter İlişkili Enfeksiyon Sıklığı; Bir Yıllık Deneyim , 2017 .

[7]  A. Kara,et al.  Cohort Study: Central Venous Catheter-Related Complications in Children with Hematologic Diseases at a Single Center , 2015, Turkish journal of haematology : official journal of Turkish Society of Haematology.

[8]  R. Hayden,et al.  No evidence of benefit from antibiotic lock therapy in pediatric oncology patients with central line‐related bloodstream infection: Results of a retrospective matched cohort study and review of the literature , 2014, Pediatric blood & cancer.

[9]  M. Chaudhary,et al.  The Impact of Ethanol Lock Therapy on Length of Stay and Catheter Salvage in Pediatric Catheter-Associated Bloodstream Infection , 2014, Clinical pediatrics.

[10]  Matthew Z. Wilson,et al.  Attributable costs of central line-associated bloodstream infections in a pediatric hematology/oncology population. , 2013, American journal of infection control.

[11]  C. V. van Ommen,et al.  Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer. , 2013, The Cochrane database of systematic reviews.

[12]  M. Hacımustafaoğlu,et al.  Catheter-associated Bloodstream Infections in Pediatric Hematology-Oncology Patients , 2013, Pediatric hematology and oncology.

[13]  Chao‐Ping Yang,et al.  Catheter-related bloodstream infection with removal of catheter in pediatric oncology patients: a 10-year experience in Taiwan , 2012, International Journal of Clinical Oncology.

[14]  A. Planes,et al.  Effectiveness of antibiotic-lock therapy for long-term catheter-related bacteremia due to Gram-negative bacilli: a prospective observational study. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  J. O’Horo,et al.  Anti-Infective Locks for Treatment of Central Line-Associated Bloodstream Infection: A Systematic Review and Meta-Analysis , 2011, American Journal of Nephrology.

[16]  E. Çiftçi,et al.  Successful treatment of central venous catheter infection due to Candida lipolytica by caspofungin‐lock therapy , 2011, Mycoses.

[17]  G. Zilleruelo,et al.  PREFABL: predictors of failure of antibiotic locks for the treatment of catheter-related bacteraemia. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  E. Anaissie,et al.  Early removal of central venous catheter in patients with candidemia does not improve outcome: analysis of 842 patients from 2 randomized clinical trials. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  I. Yaniv,et al.  Outcome of antibiotic lock technique for persistent central venous catheter-associated coagulase-negative Staphylococcus bacteremia in children , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[20]  D. Warren,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Leiva,et al.  Effectiveness of the antibiotic lock therapy for the treatment of port-related enterococci, Gram-negative, or Gram-positive bacilli bloodstream infections. , 2009, Diagnostic microbiology and infectious disease.

[22]  Z. Samra,et al.  Catheter-Associated Bloodstream Infections in Pediatric Hematology-Oncology Patients: Factors Associated With Catheter Removal and Recurrence , 2006, Journal of pediatric hematology/oncology.

[23]  W. Peetermans,et al.  Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. , 2005, The Journal of antimicrobial chemotherapy.

[24]  M. Rafferty,et al.  A prospective study of Hickman/Broviac catheters and implantable ports in pediatric oncology patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.